# US 2022/0009910 A1 · Tyrosine kinase 2 inhibitors, preparation methods and medicinal uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009910 A1
- Document ID: US20220009910A1
- Status: Published application
- Kind: A1
- Application number: 17/372,454
- Filed: 2021-07-10
- Published: 2022-01-13
- Earliest claimed: 2020-07-10
- Assignees: Eternity Bioscience Inc.
- Applicants: Eternity Bioscience Inc.
- Inventors: Linghang Zhuang; Jian Liu; Yinfa Yan; Puhui Li; Yu Zhou; Suxing Liu
- Web page: https://patentgrep.com/patent/US20220009910A1

## CPC

- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This application discloses Tyk-2 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, method of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with Tyk-2 activity, such as autoimmune diseases and cancers.

## Claims

### Claim 1

A compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
wherein:
G1 is N atom or C atom;
G2 and G3 are identical or different, and each is independently selected from the group consisting of C atom, O atom, N atom and S atom, provided that at least one of G1, G2 and G3 is a heteroatom;
W1 and W2 are identical or different, and each is independently N atom or CR6;
L is selected from the group consisting of a bond, O atom and alkylene, wherein the alkylene is optionally substituted with one or more groups independently selected from the group consisting of halogen, alkyl, alkoxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
ring A is heteroaryl;
R1 is selected from the group consisting of hydrogen, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl and —C(O)R7;
R2 is selected from the group consisting of hydrogen, halogen, alkyl, deuterated alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl and heterocyclyl;
R3 is selected from the group consisting of hydrogen, halogen, alkyl, deuterated alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, hydroxyalkyl, cyano, amino nitro, cycloalkyl and heterocyclyl;
R4 at each occurrence is independently selected from the group consisting of hydrogen, halogen, alkyl, deuterated alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R5 at each occurrence is independently selected from the group consisting of hydrogen, halogen, alkyl, oxo, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R6 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, deuterated alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R7 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl and heterocyclyl;
n is 0, 1, 2, 3 or 4; and
t is 0, 1, 2 or 3.

### Claim 2 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, being a compound of formula (II), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
wherein:
ring A, L, G1, G2, G3, W1, W2, R1 to R5, n and t are each as defined in claim 1.

### Claim 3 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein W1 is CR6, and W2 is N atom; and R6 is as defined in claim 1.

### Claim 4 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, being a compound of formula (III), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
wherein:
ring A, L, G1, G2, G3, R1 to R5, n and t are each as defined in claim 1.

### Claim 5 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein R1 is —C(O)R7, and R7 is as defined in claim 1.

### Claim 6 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein L is a bond or O atom.

### Claim 7 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, being a compound of formula (IV) or formula (V), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
wherein:
ring A, G1, G2, G3, R2 to R5, R7, n and t are each as defined in claim 1.

### Claim 8 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein
is selected from the group consisting of
and R5 is as defined in claim 1.

### Claim 9 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein R5 is each identical or different, and each is independently selected from the group consisting of hydrogen, halogen, C1-6alkyl, oxo, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyl and hydroxy C1-6alkyl.

### Claim 10 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein
is selected from the group consisting of

### Claim 11 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein ring A is 5-member heteroaryl; and preferably triazolyl.

### Claim 12 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein R2 is C1-6alkyl or deuterated C1-6alkyl.

### Claim 13 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein R3 is C1-6alkoxy.

### Claim 14 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein R4 is each identical or different, and each is independently selected from the group consisting of hydrogen and C1-6alkyl.

### Claim 15 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein R7 is C3-6cycloalkyl.

### Claim 16 (depends on 1)

The compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, wherein the compound is selected from the group consisting of:

### Claim 17 (depends on 1)

A compound of formula (IA), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
Wherein:
Rm is hydrogen or alkyl; preferably C1-6 alkyl;
ring A, L, G1, G2, G3, W1, W2, R3 to R5, n and t are each as defined in claim 1.

### Claim 18 (depends on 17)

The compound of formula (IA), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 17, wherein the compound is selected from the group consisting of:

### Claim 19 (depends on 1)

A process of preparing the compound of formula (I) according to claim 1, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, comprising a step of:
reacting a compound of formula (IA) with a compound of R2—NH2 to obtain the compound of formula (I);
wherein:
Rm is hydrogen or alkyl; preferably C1-6 alkyl;
ring A, L, G1, G2, G3, W1, W2, R1 to R5, n and t are each as defined in claim 1.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

A method of treating an Tyk2-mediated disorder, disease or condition, comprising a step of administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, or a pharmaceutical composition thereof.

### Claim 22 (depends on 1)

A method of treating proliferative, metabolic, allergic, autoimmune and inflammatory diseases, comprising a step of administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, or a pharmaceutical composition thereof.

### Claim 23 (depends on 1)

A method of treating autoimmune and inflammatory diseases, comprising a step of administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, or a pharmaceutical composition thereof.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the autoimmune and inflammatory diseases is selected from arthritis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, cutaneous lupus, inflammatory bowel disease, psoriasis, psoriatic arthritis, Crohn's disease, Sjögren's syndrome, systemic scleroderma, ulcerative colitis, Graves' disease, discoid lupus erythematosus, adult onset stills, systemic onset juvenile idiopathic arthritis, gout, gouty arthritis, type I diabetes, insulin dependent diabetes mellitus, sepsis, septic shock, Shigellosis, pancreatitis, glomerulonephritis, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, myasthenia gravis, ankylosing spondylitis, pemphigus vulgaris, Goodpasture's disease, antiphospholipid syndrome, idiopathic thrombocytopenia, ANCA-associated vasculitis, pemphigus, Kawasaki disease, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), dermatomyositis, polymyositis, uveitis, Guillain-Barre syndrome, autoimmune pulmonary inflammation, autoimmune thyroiditis, autoimmune inflammatory eye disease and chronic demyelinating polyneuropathy.

### Claim 25 (depends on 1)

A method of treating cancer, comprising a step of administering to a subject in need thereof a therapeutically effective amount of the compound of formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof according to claim 1, or a pharmaceutical composition thereof.
